ATE383858T1 - Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen - Google Patents

Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen

Info

Publication number
ATE383858T1
ATE383858T1 AT02730462T AT02730462T ATE383858T1 AT E383858 T1 ATE383858 T1 AT E383858T1 AT 02730462 T AT02730462 T AT 02730462T AT 02730462 T AT02730462 T AT 02730462T AT E383858 T1 ATE383858 T1 AT E383858T1
Authority
AT
Austria
Prior art keywords
sup
sub
compounds
linkage
oxides
Prior art date
Application number
AT02730462T
Other languages
English (en)
Inventor
Garry Fenton
Neil Victor Harris
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113708A external-priority patent/GB0113708D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of ATE383858T1 publication Critical patent/ATE383858T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT02730462T 2001-06-06 2002-06-05 Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen ATE383858T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0113708A GB0113708D0 (en) 2001-06-06 2001-06-06 Chemical compounds
US31150201P 2001-08-10 2001-08-10

Publications (1)

Publication Number Publication Date
ATE383858T1 true ATE383858T1 (de) 2008-02-15

Family

ID=26246159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730462T ATE383858T1 (de) 2001-06-06 2002-06-05 Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen

Country Status (13)

Country Link
US (1) US7211586B2 (de)
EP (1) EP1392306B1 (de)
JP (1) JP4583751B2 (de)
AT (1) ATE383858T1 (de)
AU (1) AU2002302783B2 (de)
CA (1) CA2449402C (de)
DE (1) DE60224664T2 (de)
DK (1) DK1392306T3 (de)
ES (1) ES2296926T3 (de)
IL (1) IL159203A0 (de)
MX (1) MXPA03009660A (de)
PT (1) PT1392306E (de)
WO (1) WO2002098426A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1682537T3 (pl) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
CN1933839A (zh) * 2004-01-23 2007-03-21 安进公司 化合物和使用方法
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2609053C (en) 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
WO2007050124A1 (en) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
EP3797775A1 (de) 2007-10-19 2021-03-31 Novartis AG Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
EP3632444A3 (de) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung in der lokalen behandlung von immunerkrankungen
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
TWI650321B (zh) * 2011-10-14 2019-02-11 美商安比特生物科學公司 雜環化合物及其使用方法
AU2012346214B2 (en) * 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
EP3573968A1 (de) * 2017-01-30 2019-12-04 Biogen MA Inc. Nrf2-aktivator
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2023287241A1 (ko) * 2021-07-15 2023-01-19 주식회사 휴사이온 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
EP1091943B1 (de) * 1998-06-30 2005-11-30 Pfizer Products Inc. Nicht-peptide inhibitoren von vla-4 abhängiger zellbindung für die behandlung von entzündungen, autoimmune krankheiten und atemstörungen
PL346248A1 (en) * 1998-08-26 2002-01-28 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
IL148544A0 (en) * 1999-09-24 2002-09-12 Genentech Inc Tyrosine derivatives

Also Published As

Publication number Publication date
DK1392306T3 (da) 2008-05-19
DE60224664D1 (de) 2008-03-06
AU2002302783B2 (en) 2006-11-16
PT1392306E (pt) 2008-03-07
CA2449402C (en) 2009-08-11
MXPA03009660A (es) 2004-04-02
CA2449402A1 (en) 2002-12-12
EP1392306B1 (de) 2008-01-16
JP4583751B2 (ja) 2010-11-17
EP1392306A1 (de) 2004-03-03
US7211586B2 (en) 2007-05-01
JP2005500276A (ja) 2005-01-06
IL159203A0 (en) 2004-06-01
WO2002098426A1 (en) 2002-12-12
ES2296926T3 (es) 2008-05-01
DE60224664T2 (de) 2009-01-08
US20040122047A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
DE60224664D1 (de) Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
ATE139783T1 (de) Azasteroide zur behandlung prostatischer hypertrophie, ihre herstellung und verwendung
EP0385850A3 (de) Benzimidazol- und Azabenzimidazol-Derivate, Verfahren zu deren Herstellung, Synthese-Zwischenprodukte, diese enthaltende pharmazeutische Zusammensetzungen, verwendbar bei der Behandlung von Herzgefässerkrankungen und duodenalem Ulcus
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60131160D1 (de) Caspase-inhibitoren und ihre verwendungen
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
ATE211468T1 (de) Neuraminsäuredervate, ihre herstellung und medizinische verwendung
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
DK0835868T3 (da) 2-aryl-3-aminoaryloxynaphthylforbindelser, mellemprodukter, sammensætninger og fremgangsmåder
ATE258050T1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
BR0009582A (pt) Composto, composição farmacêutica, e, processopara o tratamento de uma condição de doençaselecionada de artrite reumatóide, doença dealzheimer, câncer, esquizofrenia, edema, rinitealérgica, inflamação, dor, hipermobilidadegastrointestinal , asma gástrica, refluxogastroesfageal, ansiedade, emese, doença dehuntington, psicoses incluindo depressão,hipertensão, enxaqueca e urticária
ATE270279T1 (de) Benzofuroxanderivate und ihre verwendung zur behandlung von angina pectoris
TR200002808T2 (tr) İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
TR200102639T2 (tr) Yeni morfolin türevleri, bunları hazırlamak için proses ve bunları içeren farmasötik kompozisyonlar.
JPS6379875A (ja) 複素環式第一アミンのジセレノビス安息香酸、それを製造するための方法及びそれを含有する医薬
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
HUP0302820A2 (hu) CNS rendellenességek kezelésében hasznos indolszármazékok és ezeket tartalmazó gyógyszerkészítmények
NO992316L (no) Benzensulfonamidderivater og legemidler inneholdende disse
AP2001002314A0 (en) Substituted benzolactam compounds.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392306

Country of ref document: EP

REN Ceased due to non-payment of the annual fee